Online inquiry

IVTScrip™ mRNA-Anti-KIR3DL2, IPH4102(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9458MR)

This product GTTS-WQ9458MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets KIR3DL2 gene. The antibody can be applied in Lymphoma, cutaneous T cell (CTCL) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_001242867.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3812
UniProt ID P43630
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-KIR3DL2, IPH4102(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ9458MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14018MR IVTScrip™ mRNA-Anti-IL33, REGN-3500(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA REGN-3500
GTTS-WQ4792MR IVTScrip™ mRNA-Anti-DPP4, BT 5/9(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BT 5/9
GTTS-WQ9054MR IVTScrip™ mRNA-Anti-FLT1, IMC-18F1(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA IMC-18F1
GTTS-WQ4700MR IVTScrip™ mRNA-Anti-MAPT, BMS-986168(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BMS-986168
GTTS-WQ13436MR IVTScrip™ mRNA-Anti-TNFRSF10B, PRO95780(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA PRO95780
GTTS-WQ15049MR IVTScrip™ mRNA-Anti-CD47, SRF-231(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA SRF-231
GTTS-WQ8132MR IVTScrip™ mRNA-Anti-CD37, HH1(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA HH1
GTTS-WQ7868MR IVTScrip™ mRNA-Anti-APCS, GSK-2398852(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA GSK-2398852
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW